- Imatinib, sold
under the
brand names Gleevec and
Glivec (both
marketed worldwide by Novartis)
among others, is an oral
targeted therapy medication used...
- the
Indian Supreme Court on the
issue of
whether Novartis could patent Gleevec in India, and was the
culmination of a seven-year-long
litigation fought...
- deal),
carbamazepine (Tegretol),
valsartan (Diovan),
imatinib mesylate (
Gleevec/Glivec),
cyclosporine (Neoral/Sandimmune),
letrozole (Femara), methylphenidate...
- life. Abdul-Jabbar is a
spokesman for Novartis, the
company that
produces Gleevec, his
cancer medication. In
February 2011, Abdul-Jabbar
announced via Twitter...
-
imatinib (
Gleevec), the
first medication that
specifically targets cancer cells, for the
treatment of
chronic myeloid leukemia (CML). In 2001,
Gleevec gained...
-
Lasker Clinical Award and in 2012 the ****an
Prize for the
development of
Gleevec, also
known as Imatinib, a
selective BCR-ABL
inhibitor for the treatment...
- The
first of this new
class of
drugs was
imatinib mesylate (marketed as
Gleevec or Glivec),
approved by the US Food and Drug
Administration (FDA) in 2001...
-
protracted battle with the
government of
India over the
patenting of its drug,
Gleevec, in India,
which ended up in a
Supreme Court in a case
known as Novartis...
-
number of
children also
develop this disease. It is
treated with
imatinib (
Gleevec in
United States,
Glivec in Europe) or
other drugs. The five-year survival...
- "Breakthrough of the Year". [citation needed] 1998: A drug
called imatinib (
Gleevec), the
early work for
which was done at Dana–Farber [citation needed], achieves...
